ClinicalTrials.gg
Active, not recruitingNCT06225973Updated Jul 10, 2024

A Study of TL-925 Ophthalmic Emulsion as a Treatment for Dry Eye Disease

A Phase 2 interventional study of TL-925 and Placebo in Dry Eye Disease, sponsored by Telios Pharma, Inc.. Active, not recruiting at 18 sites in United States. Open to participants aged 18 Years and older. Per ClinicalTrials.gov, last updated 2024-07-10.

Sponsored by Telios Pharma, Inc. · Phase 2, Interventional, and Treatment

From the registry’s dates

  • Primary completion was expected by Dec 2024, 1 year 11 months ago, but the record still lists the study as active, not recruiting.

Help build ClinicalTrials.gg — short surveys, remote interviews or testing, in your language. Take part →

Phase
Phase 2
Study type
Interventional
Enrollment
880
Allocation
Randomized
Ages
18 Years and older
Sex
All
01

Where this study stands

Counted across the records on this site · 2026-11-17

Among 544 studies in Dry Eye Syndromes with a site in United States — 52 open to participants now, 63 under way, 3 of them phase 3. Dry Eye Syndromes · United States.

Planned enrollment
6th of 473
880 · median 60
Started
2024
with 31 others
Phase 2
97 of 544
5 open now
Primary completion
2024-12
later than 4 of 62 live
Registered
449th of 544
by date

Among the 544 studies in Dry Eye Syndromes with a site in United States, this one is the 6th largest by planned enrollment of the 473 interventional ones that give a count, is one of 32 that started in 2024, is one of 97 in phase 2, reaches primary completion later than 4 of the 62 other live ones, and was the 449th registered.

Dry Eye Syndromes

1,369 studies on the registry are indexed under Dry Eye Syndromes; 209 are open to participants now.

Browse Dry Eye Syndromes studies →

Open to participants now

52 of the 544 studies in Dry Eye Syndromes with a site in United States are open now. Recruiting first, the newest first:

47 more — sign in →

All 52 open studies →

A study can be open while its sites in United States have not opened yet or have stopped. Only those recruiting at a site in United States →

Who these studies take

Of the 116 Dry Eye Syndromes studies recruiting now, 73 (63%) set no upper age limit and 24 (21%) stop at 75 or younger; 7 take children under 18; 29 take healthy volunteers.

This study: 18 Years and older · all sexes · no healthy volunteers.

The full table on the hub →

This tab as a report to print or save as PDF → With an account.

Was this useful?
Get alerts for this landscapeDownload CSVNarrow it in search →With an account: a weekly mail of what changed among 544 studies in Dry Eye Syndromes with a site in United States, or all of them as a file.
02

Study summary

In this prospective, phase 2b, multicenter, randomized, double-masked, vehicle-controlled, parallel-arm study, approximately 880 subjects with moderate to severe dry eye disease (DED) will be randomly assigned (1:1) to receive either TL-925 or vehicle as topical ophthalmic eye drops administered bilaterally BID.

The study will comprise two phases: a two-week screening phase/run-in and a six-week double-masked treatment phase.

03

Conditions studied

  • Dry Eye Disease

Browse trials for

04

Who can participate

Ages eligible
18 Years and older
Sexes eligible
All
Accepts healthy volunteers
No

Go through the criteria one by one — yes, no or not sure — and take the list to your doctor or the study team. Kept in this browser only.

Inclusion criteria

  • A diagnosis of dry eye disease for at least 6 months
  • An unanesthetized Schirmer's test score (STS) of ≤ 10mm and ≥ 1mm in the study eye
  • Female subjects of and their male partners must both use a highly effective method during the study

Exclusion criteria

Exclusion Criteria:

  • Any slit lamp finding
  • Any ongoing ocular infection (bacterial, viral or fungal) or active ocular inflammation
  • Best-corrected visual acuity ≥0.7 logarithm of the minimum angle of resolution
  • Any keratorefractive surgery within the last 12 months
  • Any intraocular or extraocular surgery within 3 months
  • Any blepharoplasty or corneal transplant in either eye
  • Any form of punctual, or intracanalicular occlusion in either eye
  • History or presence of any ocular disorder that may interfere with study results
Terms in these criteria, in plain language(3)

Underlined terms in the criteria open these too. Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.

Childbearing potential

Able to become pregnant: from the first period until menopause, unless permanently unable to through surgery (removal of the womb, or of both ovaries or both fallopian tubes).

Criteria for people of childbearing potential usually ask for a negative pregnancy test and for contraception during the study and for a time after it.

Contraception

Ways of preventing pregnancy. “Highly effective” methods fail less than 1% of the time a year when used correctly — for example an IUD or an implant.

Criteria usually say which methods count and how long to keep using them after the last dose, sometimes for male participants too. Some studies accept a partner’s vasectomy if it was confirmed successful and that person is the participant’s only sexual partner.

Clinically significant

Judged by the study doctor to matter for your health or for the study. It is a doctor’s decision, so ask the study team if you are unsure whether something counts.

05

Study design

Phase
Phase 2
Primary purpose
Treatment
Allocation
Randomized
Intervention model
Parallel assignment
Masking
Triple (Participant, Care provider, Investigator)
Enrollment
880 participants (estimated)

Study arms

  • Experimental
    TL-925 Arm

    TL-925 will be administered OU BID

    Drug: TL-925

  • Placebo comparator
    Vehicle Arm

    Vehicle will be administered OU BID

    Other: Placebo

Interventions

  • DrugTL-925

    TL-925 is an eye drop.

  • OtherPlacebo

    The composition of the vehicle is identical to the active formulation except for the exclusion of the active ingredient.

06

What researchers measure

Primary outcomes

  1. To evaluate the efficacy of TL-925 compared to vehicle on tear production

    Percentage of subjects who achieve ≥10 mm improvement in Schirmer's test score

    Time frame: Baseline to Day 29

07

Study locations

18 sites
08

Timeline

Tracking since Sep 25, 2026
ElapsedEstimatedEstimated, not yet reachedSimilar studies: half by the dot; the band is the middle halfHalf of similar studies reached it by the dot; the band is the middle half, from a quarter to three quarters

Started Feb 2024 (actual). Primary completion is estimated for Dec 2024, 10 months after the start.

Of 75 industry-sponsored phase 2 interventional studies under Dry Eye Syndromes, half reached primary completion within 7 months of starting (the median), counting those still running; a quarter within 4 and three quarters within 11. This study's planned 10 months is above that.

Counting every sponsor, half of 91 studies reached it within 7 months; a quarter within 5 and three quarters within 12.

How these figures are worked out, and which studies are left out of them.

Registered
Jan 17, 2024
First posted
Jan 26, 2024
StartActual
Feb 6, 2024
Primary completionEst.
Dec 2024
CompletionEst.
Dec 2024
Last update
Jul 10, 2024
What these dates mean
Start.
When the first participant enrolled; while estimated, when the study expects to open to recruitment.
Primary completion.
When the last participant was examined or treated to collect data for the study's main question, its primary outcome. A study that stopped early gives the date its data collection stopped.
Completion.
When the last participant's last visit took place, for every outcome, secondary ones and side effects included: the end of the study. Often later than primary completion, sometimes the same day.
Actual and Est.
Actual means the registry says the date has happened. Est. (estimated) is a date the sponsor plans or expects. It can still move, and the sponsor is expected to change it to actual once it has passed.
No changes since tracking began. The registry record was last updated on Jul 10, 2024, before this site started recording changes on Sep 25, 2026. Its history is on ClinicalTrials.gov ↗
09

Registry details

Key details

Study ID
NCT06225973
Lead sponsor
Telios Pharma, Inc.
Responsible party
Sponsor
First posted
Jan 26, 2024
Start date
Feb 6, 2024
Primary completion
Dec 2024 (estimated)
Completion
Dec 2024 (estimated)
Last update
Jul 10, 2024

Oversight

FDA-regulated drug
Yes
FDA-regulated device
No
View the source record on ClinicalTrials.gov ↗

Not currently enrolling

This study is active, not recruiting, as verified in Jul 2024. You cannot join it, but the record below documents what was studied.

Follow this study

Get an email when the registry record changes — status, dates, results — or when someone posts here.

Sign in to follow

Discussion

Questions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.

Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.

Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.

Studies of the drug tested here: TL-925

Start the discussion